报价延迟最少15分钟:2025/08/25 04:51 EDT
盘前时段
|
||||
|
93.81 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
94.15
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.61/0.05
|
|
企业价值
5.25B
|
| 资产负债 |
|
每股账面净值
13.34
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
383.48M
|
|
每股收益
5.29
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/08/25 04:51 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite. |
